Shuttle Pharmaceuticals Holdings, Inc. Common Stock
SHPH
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Last trade$3.91
Day change-$0.33 (-7.78%)
Day range$3.68 – $4.38
Volume29,925
Market cap$20M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$20.2M
Price / earnings
—
Price / book
1.05×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.3×
Profitability
Earnings per share
-$2.15
Return on assets
-44.98%
Return on equity
-53.49%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.11×
Quick ratio
0.11×
Cash ratio
0.03×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SHPH, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.98M
$1.16M
$1.84M
$886.06K
$2.35M
$596.89K
$429.07K
$329K
Research and development
$55.66K
$267.24K
$511.88K
$943.48K
$1.03M
$1.57M
$986.41K
$1.4M
Total operating expenses
$3.95M
$2.22M
$2.79M
$2.27M
$3.91M
$2.95M
$1.78M
$3.05M
Operating income
-$3.95M
-$2.22M
-$2.79M
-$2.27M
-$3.91M
-$2.95M
-$1.78M
-$3.05M
Interest expense
$0
-$12.12K
-$18.25K
-$18.9K
-$21.74K
-$11.93K
-$159.28K
-$272.68K
Income before taxes
-$3.15M
-$2.15M
-$2.61M
-$2.35M
-$3.71M
-$3.05M
-$1.6M
-$3.78M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.15M
-$2.15M
-$2.61M
-$2.35M
-$3.71M
-$3.05M
-$1.6M
-$3.78M
Net income attributable to common shareholders
-$3.15M
-$2.15M
-$2.61M
-$2.35M
-$3.71M
-$3.05M
-$1.6M
-$3.78M
EBITDA
-$1.41M
-$794.46K
-$2.07M
-$1.83M
-$3.37M
-$2.17M
-$1.41M
-$1.73M
Basic earnings per share
-$3.10
-$4.30
-$9.37
-$10.50
-$32.91
-$76.00
-$81.14
-$398.30
Diluted earnings per share
-$3.10
-$4.30
-$9.37
-$10.50
-$32.91
-$76.00
-$88.50
-$398.30
Recent news
Company coverage with links to the original publishers.
E.F. Hutton & Co. announced it served as exclusive M&A advisor and placement agent for Shuttle Pharmaceuticals Holdings' acquisition of United Dogecoin Inc., creating one of the largest publicly traded Dogecoin mining platforms. The transaction included a $9.6 million PIPE financing to support mining operations expansion with next-generation equipment.
Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven drug discovery platform, for $10 million. The acquisition aims to leverage advanced machine learning models to accelerate pharmaceutical research and development.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced the closing of a $5.75 million underwritten public offering. The company plans to use the proceeds to fund its Phase II clinical trial, marketing, and general corporate purposes.
Shuttle Pharmaceuticals has successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma, a deadly brain cancer. The company has also finalized agreements with six clinical trial sites and raised additional funding to support the trial.
Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a $4.5 million public offering, with the proceeds to be used for clinical trials and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.